<DOC>
	<DOC>NCT00870402</DOC>
	<brief_summary>The purpose of this study is to determine whether spironolactone are effective in the reduction of albuminuria and diastolic disfunction of subjects with diabetic nephropathy.</brief_summary>
	<brief_title>Aldosterone in Diabetic Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Diabetic subjects with maximum ten years after diagnostic Diabetic nephropathy with albuminuria Normal renal function Diastolic disfunction Taking a IECA or ARA drug family previously Diabetics subjects with macroangiopathy Acute coronary syndrome in the three months before Hyperkalemia &gt; 5.5 mEq/L Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>aldosterone</keyword>
	<keyword>albuminuria</keyword>
	<keyword>diastolic disfunction</keyword>
	<keyword>hyperkalemia</keyword>
</DOC>